3.10
price down icon5.49%   -0.18
after-market アフターアワーズ: 3.12 0.02 +0.65%
loading
前日終値:
$3.28
開ける:
$3.26
24時間の取引高:
3.50M
Relative Volume:
0.86
時価総額:
$674.88M
収益:
$35.54M
当期純損益:
$-59.14M
株価収益率:
-8.5235
EPS:
-0.3637
ネットキャッシュフロー:
$-80.19M
1週間 パフォーマンス:
-4.32%
1か月 パフォーマンス:
-17.33%
6か月 パフォーマンス:
-45.52%
1年 パフォーマンス:
+41.55%
1日の値動き範囲:
Value
$3.10
$3.281
1週間の範囲:
Value
$3.10
$3.43
52週間の値動き範囲:
Value
$1.72
$8.21

Cytomx Therapeutics Inc Stock (CTMX) Company Profile

Name
名前
Cytomx Therapeutics Inc
Name
セクター
Healthcare (1079)
Name
電話
650.515.3185
Name
住所
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Name
職員
69
Name
Twitter
@cytomxinc
Name
次回の収益日
2026-08-06
Name
最新のSEC提出書
Name
CTMX's Discussions on Twitter

Compare CTMX vs VRTX, REGN, ARGX, RVMD, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
CTMX icon
CTMX
Cytomx Therapeutics Inc
3.10 707.53M 35.54M -59.14M -80.19M -0.3637
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
477.10 121.57B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
762.63 69.95B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
853.82 55.61B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
187.53 39.98B 742.00K -1.37B -1.07B -7.0731
ONC icon
ONC
Beone Medicines Ltd Adr
316.01 33.81B 5.76B 514.49M 1.10B 4.4813

Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-03-16 アップグレード JP Morgan Neutral → Overweight
2026-01-20 開始されました Guggenheim Buy
2025-09-22 開始されました Cantor Fitzgerald Overweight
2025-09-17 再開されました Barclays Overweight
2025-07-31 開始されました Oppenheimer Outperform
2025-05-15 アップグレード H.C. Wainwright Neutral → Buy
2025-04-14 再開されました Piper Sandler Overweight
2024-05-28 アップグレード Piper Sandler Neutral → Overweight
2024-05-09 アップグレード Wedbush Neutral → Outperform
2024-05-06 アップグレード Jefferies Hold → Buy
2024-04-22 アップグレード JP Morgan Underweight → Neutral
2022-11-14 ダウングレード BMO Capital Markets Outperform → Market Perform
2022-07-07 ダウングレード Jefferies Buy → Hold
2022-07-07 ダウングレード Mizuho Buy → Neutral
2022-07-07 ダウングレード Piper Sandler Overweight → Neutral
2022-07-07 ダウングレード Wedbush Outperform → Neutral
2022-06-24 開始されました BMO Capital Markets Outperform
2022-01-18 アップグレード Barclays Underweight → Overweight
2021-11-15 開始されました BTIG Research Buy
2021-05-28 ダウングレード Barclays Equal Weight → Underweight
2021-03-29 開始されました JP Morgan Overweight
2021-03-23 アップグレード Jefferies Hold → Buy
2020-09-22 ダウングレード Guggenheim Buy → Neutral
2020-06-01 ダウングレード Jefferies Buy → Hold
2020-05-14 繰り返されました H.C. Wainwright Buy
2020-03-24 アップグレード Wedbush Neutral → Outperform
2020-03-04 開始されました Barclays Equal Weight
2019-11-20 開始されました Guggenheim Buy
2019-11-11 ダウングレード Wedbush Outperform → Neutral
2019-06-13 開始されました Mizuho Buy
2019-05-14 開始されました Cantor Fitzgerald Overweight
2019-03-11 開始されました Barclays Overweight
2018-11-26 開始されました Piper Jaffray Overweight
2018-10-15 開始されました Goldman Neutral
2018-09-13 開始されました H.C. Wainwright Buy
2018-06-01 開始されました SunTrust Buy
2018-01-05 開始されました Citigroup Buy
2017-09-08 開始されました Wedbush Outperform
2017-03-27 開始されました H.C. Wainwright Buy
2017-03-02 開始されました Instinet Buy
2017-01-03 ダウングレード Oppenheimer Outperform → Perform
2015-11-02 開始されました Oppenheimer Outperform
すべてを表示

Cytomx Therapeutics Inc (CTMX) 最新ニュース

pulisher
Jul 27, 2026

BlackRock (CTMX holder) discloses 7.6% beneficial stake in CytomX Therapeutics - Stock Titan

Jul 27, 2026
pulisher
Jul 27, 2026

CytomX appoints Charles Fuchs to board of directors By Investing.com - Investing.com South Africa

Jul 27, 2026
pulisher
Jul 27, 2026

CytomX Therapeutics Inc (CTMX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors - The Manila Times

Jul 27, 2026
pulisher
Jul 27, 2026

Charles Fuchs appointed to CytomX Board as Class II director - TradingView

Jul 27, 2026
pulisher
Jul 27, 2026

More Than Three Decades in Oncology: Fuchs Joins CytomX Board - Stock Titan

Jul 27, 2026
pulisher
Jul 26, 2026

CytomX Therapeutics Inc (CTMX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Jul 26, 2026
pulisher
Jul 26, 2026

CytomX Therapeutics Inc (CTMX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Jul 26, 2026
pulisher
Jul 26, 2026

CTMX|CytomX Therapeutics Inc|Price:3.240|Chg%:-0.090 - TradingKey

Jul 26, 2026
pulisher
Jul 25, 2026

TradingKey - TradingKey

Jul 25, 2026
pulisher
Jul 24, 2026

CytomX Therapeutics Inc (CTMX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jul 24, 2026
pulisher
Jul 21, 2026

CTMX stock holds focus after CytomX strategy update - Ad-hoc-news.de

Jul 21, 2026
pulisher
Jul 16, 2026

CytomX Therapeutics, Inc.Common Stock (NQ: CTMX - FinancialContent

Jul 16, 2026
pulisher
Jul 14, 2026

CTMX Stock Garners Price Target Revisions After Colorectal Cancer Trial Data: Jefferies Sees As Much As 230% Upside - Stocktwits

Jul 14, 2026
pulisher
Jul 09, 2026

CytomX Therapeutics (CTMX) Holds Near Support After Slight DipUpthrust Pattern - dars.gov.et

Jul 09, 2026
pulisher
Jul 08, 2026

CytomX Therapeutics updates investors on its pipeline progress amid Nasdaq listing - Ad-hoc-news.de

Jul 08, 2026
pulisher
Jul 08, 2026

CytomX Therapeutics (CTMX) Upgraded to Buy: Here's Why - Yahoo Finance

Jul 08, 2026
pulisher
Jul 07, 2026

CytomX Therapeutics focuses on its antibody-drug conjugate platform - Ad-hoc-news.de

Jul 07, 2026
pulisher
Jul 05, 2026

Maxim Says Context Therapeutics (CNTX)’s Share Pullback Is an Overreaction; Remains Bullish - Yahoo Finance

Jul 05, 2026
pulisher
Jul 03, 2026

CytomX Therapeutics outlines its oncology focus as investors watch Nasdaq trading - ad-hoc-news.de

Jul 03, 2026
pulisher
Jun 30, 2026

CTMX Stock Pulls Back After 5-Year High: Share Sale Sparks Dilution Fears Despite Wall Street’s 150% Upside Calls - Stocktwits

Jun 30, 2026
pulisher
Jun 29, 2026

CytomX Therapeutics, Inc.(NasdaqGS:CTMX) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell 2000 Index - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell 2000 Value Benchmark - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

CytomX Therapeutics, Inc.(NasdaqGS:CTMX) added to Russell Microcap Value Benchmark Index - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell 2000 Growth Benchmark - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell 3000E Index - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell Microcap Index - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell 3000E Growth Benchmark - marketscreener.com

Jun 29, 2026
pulisher
Jun 28, 2026

CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell 3000 Index - marketscreener.com

Jun 28, 2026
pulisher
Jun 28, 2026

CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell 3000 Growth Benchmark - marketscreener.com

Jun 28, 2026
pulisher
Jun 27, 2026

Price to book forward of CytomX Therapeutics, Inc. – NASDAQ:CTMX - TradingView

Jun 27, 2026
pulisher
Jun 27, 2026

Price to earnings forward of CytomX Therapeutics, Inc. – NASDAQ:CTMX - TradingView

Jun 27, 2026
pulisher
Jun 27, 2026

Enterprise value to EBIT forward of CytomX Therapeutics, Inc. – NASDAQ:CTMX - TradingView

Jun 27, 2026
pulisher
Jun 26, 2026

Price to sales forward of CytomX Therapeutics, Inc. – NASDAQ:CTMX - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

Enterprise value to revenue forward of CytomX Therapeutics, Inc. – NASDAQ:CTMX - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

CytomX Therapeutics, Inc. Actuals & Estimates (NASDAQ:CTMX) - TradingView

Jun 26, 2026
pulisher
Jun 25, 2026

CTMX Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026
pulisher
Jun 23, 2026

CytomX Shareholders Approve Expanded Equity and Capital Plans - The Globe and Mail

Jun 23, 2026
pulisher
Jun 23, 2026

Form 4 CytomX Therapeutics Inc For: 22 June By Investing.com - Investing.com India

Jun 23, 2026
pulisher
Jun 22, 2026

CytomX Therapeutics Amends Equity Incentive and Employee Stock Purchase Plans Following 2026 Shareholder Approval – Minichart - Minichart

Jun 22, 2026
pulisher
Jun 22, 2026

CytomX Therapeutics stockholders approve share increases and board elections - Investing.com

Jun 22, 2026
pulisher
Jun 22, 2026

CytomX Therapeutics stockholders approve share increases and board elections By Investing.com - Investing.com Canada

Jun 22, 2026
pulisher
Jun 22, 2026

Form 8K CytomX Therapeutics Inc For: 22 June By Investing.com - Investing.com South Africa

Jun 22, 2026
pulisher
Jun 22, 2026

CytomX (CTMX) director Su Zhen awarded 59,000 stock options at $2.96 - Stock Titan

Jun 22, 2026
pulisher
Jun 22, 2026

[8-K] CytomX Therapeutics, Inc. Reports Material Event - Stock Titan

Jun 22, 2026
pulisher
Jun 22, 2026

Director at CytomX (NASDAQ: CTMX) awarded 59,000 stock options - Stock Titan

Jun 22, 2026
pulisher
Jun 22, 2026

Director at CytomX (NASDAQ: CTMX) receives 59,000-stock option award - Stock Titan

Jun 22, 2026
pulisher
Jun 22, 2026

CytomX (CTMX) director receives 59,000 stock options at $2.96 - Stock Titan

Jun 22, 2026
pulisher
Jun 22, 2026

CytomX (CTMX) director Halley Gilbert receives 59,000 stock options at $2.96 strike - Stock Titan

Jun 22, 2026
pulisher
Jun 22, 2026

CytomX (CTMX) director Alan Ashworth receives grant of 59,000 stock options - Stock Titan

Jun 22, 2026

Cytomx Therapeutics Inc (CTMX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Cytomx Therapeutics Inc (CTMX) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Chu Yu-Waye
Chief Medical Officer
Mar 17 '26
Sale
6.42
21,279
136,675
189,446
McCarthy Sean A.
CEO
Mar 17 '26
Sale
6.42
118,969
764,138
1,078,922
BELVIN MARCIA
SVP, Chief Scientific Officer
Mar 17 '26
Sale
6.42
31,492
202,273
300,760
Ogden Christopher
Chief Financial Officer
Mar 17 '26
Sale
6.42
19,323
124,112
296,948
McCarthy Sean A.
CEO
Nov 06 '25
Sale
4.54
101,793
461,906
987,891
$90.58
price down icon 2.44%
$119.52
price down icon 2.82%
$33.91
price down icon 1.77%
$58.43
price down icon 1.00%
$205.52
price up icon 0.02%
ONC ONC
$316.01
price down icon 1.88%
大文字化:     |  ボリューム (24 時間):